{"filings":[{"id":972716,"accession_number":"0000055529-26-000014","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2026-06-10T20:07:17+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific sets Q4 and FY2026 earnings release for June 23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Results for quarter and fiscal year ended April 30, 2026 will be released after market close on June 23, 2026.","Press release will be available on the company's website at www.kewaunee.com.","No preliminary financial results or guidance were disclosed in today's announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113581,"accession_number":"0000055529-26-000006","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q3 sales +3.3% to $69.4M; diluted EPS $0.23 vs $0.45; backlog down 17% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $69.4M (+3.3% YoY); pre-tax earnings $1.6M (+25.8%).","Net earnings attributable to Kewaunee $692K (diluted EPS $0.23) vs $1.35M ($0.45) prior year.","Domestic segment sales -2.0% to $50.95M; International segment sales +21.4% to $18.45M.","Order backlog $183.2M on Jan 31, 2026, down from $221.6M a year ago.","Long-term debt net of sale-leaseback reduced to $16.3M from $34.1M at fiscal year end."],"consensus_eps_estimate":null,"consensus_eps_actual":2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":210599000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":113580,"accession_number":"0000055529-26-000003","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific sets Q3 FY2026 earnings release for March 11, 2026","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Earnings release scheduled for Wednesday, March 11, 2026 after market close.","No preliminary financial results or guidance provided in the announcement.","Results will be posted on the company's website after release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129978,"accession_number":"0000055529-25-000051","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q2 FY2026: sales +46.8% to $70.1M, diluted EPS $0.82 vs $1.01","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales up 46.8% to $70.1M; net earnings $2.45M (-18.7%); diluted EPS $0.82 (vs $1.01).","Domestic sales $55.2M (+51.7%) driven by Nu Aire; segment earnings $3.6M (down from $4.5M).","International sales $14.9M (+31.0%) on large project deliveries; segment earnings $0.64M vs $0.36M.","Backlog $192.9M (near record); management reports strong quoting but expects delivery volatility.","Debt-to-equity improved to 0.88x; early repayment of Seller Notes strengthens balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":1.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":141200000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129977,"accession_number":"0000055529-25-000048","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Kewaunee repays $23M seller notes early with new $10M term loan and revolver draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered First Amendment with PNC Bank for additional $10M term loan and revolver access to fund repayment.","Repaid in full $23M principal on seller notes (8% interest, due Nov 2027) from Nu Aire acquisition.","CFO cites consistent legacy performance, accretive Nu Aire contribution, and disciplined cash management.","Refinancing reduces overall debt load, effective interest rate, and expected future interest expense."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":129976,"accession_number":"0000055529-25-000044","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-11-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific sets Q2 FY2026 earnings release for December 10, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company will release Q2 fiscal 2026 results on December 10, 2025 after market close.","No financial data or guidance provided in the announcement.","Results will be posted on the company's website www.kewaunee.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146568,"accession_number":"0000055529-25-000038","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"Kewaunee Scientific appoints J. Jette Campbell as Class II director; bylaws amended for board size","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["J. Jette Campbell appointed to Board of Directors, effective Sept. 10, 2025; term expiring at 2027 annual meeting.","Campbell is a CPA, partner at Carl Marks Advisors, and former executive at PepsiCo, Frito-Lay, and Griffin LLC.","Appointed to Audit Committee; Board determined independent under Nasdaq and SEC rules.","Will receive standard non-employee director compensation and pro-rated equity grant for fiscal 2026.","Bylaws amended to set board size between five and nine directors, effective September 10, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146567,"accession_number":"0000055529-25-000033","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q1 sales up 47%; EPS $1.04; backlog $205M; expects FY EBITDA increase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $71.1M (+46.9% YoY); diluted EPS $1.04 vs $0.74; net earnings $3.09M.","Domestic sales $54.4M (+53%) driven by Nu Aire acquisition and improved productivity.","Backlog $205M near historical highs; CEO warns of uneven quarterly performance ahead.","Expects better unadjusted EBITDA in FY2026 vs FY2025 despite strategic investments.","Corporate segment pre-tax loss $3.1M due to SOX 404(b) compliance and growth investments."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":71104000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146566,"accession_number":"0001193125-25-192132","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kewaunee Scientific shareholders re-elect directors, ratify auditors, approve exec comp, set annual advisory vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Margaret B. Pyle and Donald F. Shaw were re-elected as Class III directors with 1,633,067 and 1,730,171 votes for, respectively.","Shareholders ratified the appointment of Forvis Mazars, LLP as independent auditors for fiscal year 2026 with 2,356,636 in favor, 2,119 against, 990 abstained.","Executive compensation was approved on an advisory basis with 1,448,991 votes for, 103,177 against, and 270,128 abstained.","Advisory vote on frequency of executive compensation: 1,512,884 votes for every one year, leading to annual say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146565,"accession_number":"0001193125-25-189068","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kewaunee Scientific posts investor presentation for annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Company posted investor presentation and script on its website under Investor Information.","Presentation will be delivered at virtual annual meeting on August 27, 2025 at 11:00 a.m. ET.","Presentation includes reconciliation of non-GAAP financial measures to GAAP.","Forward-looking statements are included; company cautions against undue reliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":146564,"accession_number":"0000055529-25-000030","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific announces Q1 FY2026 earnings release date of Sept 10, 2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["First quarter fiscal 2026 results to be released on Wednesday, September 10, 2025 after market close.","No preliminary financial information provided in the announcement; results will be available on www.kewaunee.com.","Press release dated August 27, 2025 confirms the schedule; no other material events disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164943,"accession_number":"0000055529-25-000022","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q4 sales up 36% to $77.1M; EPS $1.63, backlog $214.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $77.1M, +36% YoY; pre-tax earnings $7.1M vs $1.3M prior year quarter (which included non-recurring pension charge).","Diluted EPS $1.63; prior-year Q4 GAAP EPS $3.71 included $10.5M tax benefits; adjusted prior-year EPS was $1.55.","EBITDA $9.7M vs $2.3M prior year (adjusted prior-year EBITDA $6.3M).","Order backlog $214.6M at April 30, 2025, up 38% from $155.6M a year ago; slight sequential decline from $221.6M.","GAAP net earnings $4.9M vs $11.0M prior year due to non-recurring pension and tax items; core operations improved."],"consensus_eps_estimate":null,"consensus_eps_actual":3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":240472000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":164942,"accession_number":"0000055529-25-000019","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific to report Q4 and FY2025 results on June 25, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Results for fourth quarter and fiscal year ended April 30, 2025 to be released June 25 after market close.","No preliminary financial figures, guidance, or other material information provided in the announcement.","Press release will be available on company website www.kewaunee.com after release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182660,"accession_number":"0000055529-25-000009","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific expands share repurchase authorization by 100,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to additional 100,000 shares under existing program; no expiration date.","As of March 12, 2025, 11,176 shares remained authorized prior to amendment.","CEO cited confidence in strategy; repurchases resumed Feb 28, 2025 after Nu Aire acquisition closed Nov 1, 2024.","Repurchases may be made via open-market, block trades, or other methods at management's discretion.","Program does not obligate company to acquire any shares and may be suspended or discontinued anytime."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182659,"accession_number":"0000055529-25-000007","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Q3 revenue +44% to $67.2M; adj. diluted EPS $1.09 vs $0.85","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.45 vs $0.85; net earnings $1.4M vs $2.5M; includes $2.5M Nu Aire acquisition & integration costs.","Adjusted diluted EPS $1.09; adjusted pre-tax earnings $3.8M (+7.8% YoY); adjusted EBITDA $5.7M vs $4.4M.","Backlog hit record $221.6M vs $152.3M a year ago; Domestic segment sales jumped 63.6%, boosted by Nu Aire.","Completed Nu Aire acquisition on Nov 1, 2024; long-term debt rose to $65.8M from $28.5M to fund deal.","International segment sales flat at $15.2M; customer site delays impacted billings; record backlog in India."],"consensus_eps_estimate":null,"consensus_eps_actual":2.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":163324000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182658,"accession_number":"0000055529-25-000003","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific sets Q3 FY2025 earnings release for March 12, 2025","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company will release Q3 FY2025 financial results after market close on Wednesday, March 12, 2025.","Results will be posted on the company's website www.kewaunee.com after release.","No preliminary financial data or guidance is provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":182657,"accession_number":"0001193125-25-007212","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K/A","filed_at":"2025-01-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Kewaunee closes Nu Aire acquisition for $55M; audited Nu Aire FY24 net income $5.44M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Kewaunee acquired Nu Aire for $55M on Nov 1, 2024, using $35M bank financing and $23M seller notes at 8%.","Nu Aire FY2024 revenue $74.85M (down 8% YoY), net income $5.44M (up 84% from $2.96M).","Nu Aire had no debt, $13.46M cash; acquisition enterprise value ~$41.5M.","Nu Aire gross margin improved to 31.6% in FY2024 from 28.3% in FY2023.","Pro forma financials filed; combined entity with increased scale and profitability profile."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199234,"accession_number":"0000055529-24-000037","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q2 FY2025: Sales down 5.3%, diluted EPS $1.01 vs $0.93 YoY; backlog record $184.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $47.8M (down 5.3% YoY); domestic sales up 6.5%, international down 30.1% due to India construction delays.","Diluted EPS $1.01 vs $0.93 YoY; net earnings $3.0M vs $2.7M; EBITDA $4.9M.","Record backlog $184.4M (Oct 31, 2024) vs $146.3M a year ago and $155.6M at April 30, 2024.","Domestic segment net earnings $4.5M (up from $3.1M); international net earnings $0.4M (down from $0.5M).","Incurred $2.3M in acquisition-related expenses for Nu Aire (closed Nov 1, 2024); adjusted diluted EPS would be $1.41."],"consensus_eps_estimate":null,"consensus_eps_actual":1.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":96157000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199233,"accession_number":"0000055529-24-000034","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific announces Q2 FY2025 earnings release date: Dec 11, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Earnings will be released after the close of trading on December 11, 2024.","Results will be available on the company's website at www.kewaunee.com.","No preliminary financial results or guidance were disclosed in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":199232,"accession_number":"0001193125-24-249232","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["1.01","2.01","2.03","7.01","9.01"],"status":"ready","headline":"Kewaunee Scientific acquires Nu Aire for $55M; expands life sciences product line","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total purchase price $55M, funded with $32M cash (PNC revolver & term loan) and $23M seller notes at 8%.","PNC financing includes $20M revolver and $15M term loan maturing Nov 2029; seller notes mature in 3 years.","Nu Aire manufactures biosafety cabinets, CO2 incubators, ultralow freezers; serves life sciences, healthcare, education.","Bill Peters remains Nu Aire President and joins Kewaunee as VP; company cites operational synergies and expanded market reach.","Management expects combined product portfolio and channel strategy to drive sustainable growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215273,"accession_number":"0000055529-24-000027","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q1 FY2025 sales down 2.9%, EPS $0.74 vs $0.86, backlog up 13%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $48.4M, down 2.9% YoY; diluted EPS $0.74 vs $0.86 in prior year quarter.","Domestic net earnings rose to $2.9M from $2.7M; International sales fell 10.7% due to India site delays.","Order backlog grew to $159.4M from $140.8M a year ago (+13%).","Adjusted EBITDA (excl. professional fees) $4.1M; professional fees unrelated to core business increased.","Management sees strong backlog and quoting activity for another strong year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":48393000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215272,"accession_number":"0001193125-24-209910","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kewaunee Scientific shareholders re-elect director, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Keith M. Gehl re-elected with ~1.4M votes for, 273K withheld, 740K non-votes.","Ratification of Forvis Mazars, LLP as FY2025 auditor: ~2.41M for, 2.5K against, 1.1K abstain.","Advisory say-on-pay approved with ~1.44M for, 3K against, 234K abstain, 740K non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215271,"accession_number":"0001193125-24-208109","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kewaunee Scientific posts investor presentation for annual meeting; no material new info disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company held virtual annual shareholder meeting on August 28, 2024.","Investor presentation and script posted to company website under Investor Information.","No specific financial results or guidance changes were provided in the filing.","Presentation includes forward-looking statements and non-GAAP reconciliations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":215270,"accession_number":"0000055529-24-000024","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-08-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific to release Q1 FY2025 earnings on September 11, 2024","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Results will be reported after market close on Wednesday, September 11, 2024.","Q1 fiscal year 2025 financials will be available on the company's website.","No pre-announcement of results or guidance changes provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234587,"accession_number":"0000055529-24-000018","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Q4 sales up 5%, adjusted EPS $1.55 vs $0.34; backlog rises to $155.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 sales $56.7M (+5% YoY); GAAP net earnings $11.0M (diluted EPS $3.71) include two non-recurring items.","Adjusted pre-tax earnings $5.37M (+131% YoY); adjusted diluted EPS $1.55 vs $0.34.","Adjusted EBITDA for Q4 $6.28M vs $3.31M prior year; order backlog $155.6M (up from $147.9M a year ago).","Domestic segment sales $35.9M (+2.1% YoY); segment net earnings $3.41M vs $2.40M.","Non-recurring transactions impacted GAAP results; management provides adjusted non-GAAP metrics for comparability."],"consensus_eps_estimate":null,"consensus_eps_actual":6.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":203755000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234586,"accession_number":"0000055529-24-000015","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific schedules Q4/fiscal year 2024 earnings release for June 26","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["No financial results or guidance provided in this filing; only the release date is announced.","Results will be posted after market close on June 26, 2024, on the company's website.","Investor should wait for the actual earnings report for material financial information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":234585,"accession_number":"0001193125-24-105935","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kewaunee Scientific terminates pension plan, transfers $17.7M obligations via annuity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pension plan terminated effective April 30, 2024; $17.7M in obligations transferred via group annuity contracts.","Company contributed $0.3M cash to fully fund remaining defined benefit pension liabilities.","Benefits for participants and beneficiaries unchanged; participants to receive separate details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252449,"accession_number":"0001193125-24-075248","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Thomas Hull III enters $250K retention bonus with 3-year clawback","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Retention bonus of $250,000 payable within 10 days of March 18, 2024 effective date.","Full repayment required if CEO resigns without Good Reason or is terminated for Cause within 36 months.","Definitions of Cause and Good Reason incorporated from existing Change of Control Employment Agreement.","Agreement can only be amended in writing; governed by North Carolina law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252448,"accession_number":"0000055529-24-000006","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Q3 FY2024 EPS $0.85 vs $0.25 YoY; net income triples despite 23% sales drop","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $46.8M, down 23% YoY from $60.8M; net income $2.5M vs $0.7M.","Diluted EPS $0.85 (prior year $0.25); EBITDA $4.4M vs $2.7M.","Domestic segment net income rose to $2.6M from $0.4M on improved productivity.","International sales fell 39% to $15.0M due to two large non-recurring projects.","Cash on hand $27.1M, up from $13.8M at April 2023; debt-to-equity improved to 0.87."],"consensus_eps_estimate":null,"consensus_eps_actual":2.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":147053000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":252447,"accession_number":"0000055529-24-000003","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific to report Q3 FY2024 earnings on March 6, 2024 after market close","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Earnings release scheduled for Wednesday, March 6, 2024 after close of trading.","Results will be available on the company's website at www.kewaunee.com.","No preliminary financial results or guidance provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269964,"accession_number":"0000055529-23-000025","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific swings to Q2 profit of $2.7M; EPS $0.93 vs -$0.09","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Sales $50.4M, down 7.6% YoY; net earnings $2.7M vs loss of $243K.","Domestic segment net income surged to $3.054M from $491K on strategic shift.","EBITDA $5.66M vs $1.25M; backlog $146.3M.","Company began stock repurchase program in Q2; plans continued buybacks."],"consensus_eps_estimate":null,"consensus_eps_actual":1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":100275000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269963,"accession_number":"0000055529-23-000022","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kewaunee Scientific to release Q2 FY2024 earnings on Dec 6, 2023","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Q2 fiscal 2024 results scheduled for release on December 6, 2023 after market close.","Results will be posted on company website www.kewaunee.com.","No preliminary financial results or guidance provided in this announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286940,"accession_number":"0000055529-23-000017","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-09-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific Q1 net earnings $2.47M vs loss of $0.75M YoY; EPS $0.86 vs ($0.27)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings of $2.47M ($0.86 diluted EPS) vs net loss of $0.75M ($0.27 loss) in prior Q1.","Sales of $49.8M, down 0.6% YoY; Domestic sales fell 5.5% to $35.4M, International up 13.9% to $14.4M.","EBITDA rose to $4.3M from $0.28M; backlog was $140.8M vs $174.0M a year ago and $147.9M on April 30.","Domestic segment net income $2.71M vs $0.098M; improved due to stop selling direct, better productivity.","Cash increased to $21.6M from $13.8M (April 30); debt-to-equity 1.05-to-1."],"consensus_eps_estimate":null,"consensus_eps_actual":0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":49839000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286939,"accession_number":"0001193125-23-221501","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Kewaunee shareholders approve 2023 Omnibus Incentive Plan with 374,633 new shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plan authorizes 374,633 shares; approved by 1,419,893 for, 498,027 against.","Maximum annual director award values: $250k for Chair, $200k for other directors.","Plan replaces Prior Plans (2008 Key Employee Stock Option, 2017 Omnibus Incentive).","Plan term ends 10 years from effective date; no option repricing without stockholder vote.","Also re-elected directors Hull, Rhind, Russell and ratified FORVIS as independent auditor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286938,"accession_number":"0001193125-23-218499","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kewaunee Scientific posts investor presentation for annual meeting; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation and script posted to company website and furnished as Exhibits 99.1 and 99.2.","Presentation delivered at virtual annual meeting on August 23, 2023; replay available for one year.","No specific financial results, guidance, or material operational updates were provided in the exhibits.","Company made reference to non-GAAP financial measures; reconciliation included in presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306948,"accession_number":"0000055529-23-000009","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Scientific posts Q4 profit of $0.34/share; FY revenue up 30% to $219.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net earnings $1,005,000 ($0.34 diluted EPS) vs net loss of $362,000 ($0.13 loss) in prior year.","Q4 sales $53,986,000, up 8.6% YoY; International segment sales surged 57.3% to $18,863,000.","Full fiscal year 2023 net earnings $738,000 ($0.25 EPS) vs net loss $6,126,000 ($2.20 loss); sales up 30% to $219,494,000.","EBITDA for FY2023 improved to $7,517,000 from $394,000; domestic segment returned to profit.","Backlog at April 30, 2023 was $147.9 million, down from $173.9 million a year ago; cash increased to $13.8 million from $6.9 million."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":219494000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":326029,"accession_number":"0000055529-23-000003","cik":55529,"company_name":"KEWAUNEE SCIENTIFIC CORP /DE/","ticker":"KEQU","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kewaunee Q3 net income $723K ($0.25 EPS) vs loss; sales up 49.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net earnings $723K ($0.25 diluted EPS) vs net loss $1,319K (-$0.47); sales $60.8M, +49.7% YoY.","Domestic segment sales $36.1M (+22.4%), net income $417K vs prior year loss of $305K.","International segment sales $24.7M (+122.4%), net income $1.56M vs $573K; backlog $153.2M.","Awarded multi-year contract to supply lab products to Indian Oil Corporation Limited.","Cash $18.4M vs $6.9M; debt-to-equity 1.22:1; short-term debt $5.8M, long-term debt $29.2M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":165508000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114512331.95614961,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}